FDA seeks additional data on Takeda diabetes drug applications
Alogliptin is a DPP-4 inhibitor that is being investigated in the US, as an adjunct to diet and exercise, for the treatment of type 2 diabetes. The FDA
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.